Parabilis Medicines closed a $305 million Series F to advance its Helicon peptide platform aimed at intracellular and previously 'undruggable' targets. The funding, led by major crossover and life‑science investors, raises the company’s firepower to push its lead candidate zolucatetide toward later‑stage development. Parabilis said the capital will support expanded clinical programs and continued platform work; executives indicated the round sets up an eventual public listing. Multiple outlets noted the raise amid a broader rebound in biotech venture activity and IPO sentiment as companies look to scale translational pipelines.